Name | Abeprazan |
---|---|
Synonyms |
1-{5-(2,4-Difluorophenyl)-1-[(3-fluorophenyl)sulfonyl]-4-methoxy-1H-pyrrol-3-yl}-N-methylmethanamine
Abeprazan 1H-Pyrrole-3-methanamine, 5-(2,4-difluorophenyl)-1-[(3-fluorophenyl)sulfonyl]-4-methoxy-N-methyl- |
Description | Abeprazan is an acid pump inhibitor. |
---|---|
Related Catalog | |
In Vitro | The mechanism of action of Abeprazan is reversibly binding to H+, K+‐ATPase, and, unlike that of PPIs, does not require acidic environment for drug activation[1]. |
In Vivo | DWP14012 inhibited acid secretion in a dose-dependent manner and the inhibition of gastric acid secretion was equal to or greater than that of vonoprazan, a previously approved P-CAB, in various in vivo studies using pylorus-ligated rats, lumen-perfused rat models and heidenhain pouch dog models[1]. |
References |
Density | 1.4±0.1 g/cm3 |
---|---|
Boiling Point | 497.9±55.0 °C at 760 mmHg |
Molecular Formula | C19H17F3N2O3S |
Molecular Weight | 410.410 |
Flash Point | 254.9±31.5 °C |
Exact Mass | 410.091187 |
LogP | 3.89 |
Vapour Pressure | 0.0±1.3 mmHg at 25°C |
Index of Refraction | 1.575 |
Storage condition | 2-8°C |